TY - JOUR T1 - Sequencing individual genomes with recurrent deletions reveals allelic architecture and disease loci for autosomal recessive traits JF - medRxiv DO - 10.1101/2021.02.16.21251842 SP - 2021.02.16.21251842 AU - Bo Yuan AU - Katharina Schulze AU - Nurit Assia Batzir AU - Jefferson Sinson AU - Hongzheng Dai AU - Wenmiao Zhu AU - Francia Bocanegra AU - Chin-To Fong AU - Jimmy Holder AU - Joanne Nguyen AU - Christian P. Schaaf AU - Yaping Yang AU - Weimin Bi AU - Christine Eng AU - Chad Shaw AU - James R. Lupski AU - Pengfei Liu Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/12/2021.02.16.21251842.abstract N2 - In medical genetics, discovery and characterization of disease contributory genes and alleles depends on genetic reasoning, study design, and patient ascertainment. We present novel genomic insights to enhance discovery in the challenging context of autosomal recessive (AR) traits and bi-allelic variation. We demonstrate computationally that new mutation mediated by nonallelic homologous recombination (NAHR), involving recurrent deletions at 30 genomic regions, likely drives recessive disease burden for over 70% of loci within these segmental deletions or 2% of loci genome wide. Meta-analyses of literature-reported patients suggest that NAHR-deletions are depleted from the ascertained pool of AR trait alleles. Exome reanalysis on subjects harboring recurrent deletions uncovered new disease-contributing variants in genes including COX10, ERCC6, PRRT2 and OTUD7A. Our data implicate that genomic sequencing of personal genomes with NAHR-deletions could dramatically foment allele and gene discovery, enhance clinical molecular diagnosis, and could potentially enable human haploid genetics screens.Competing Interest StatementBaylor College of Medicine (BCM) and Miraca Holdings Inc. have formed a joint venture with shared ownership and governance of Baylor Genetics (BG), which performs clinical exome sequencing and chromosomal microarray genomics assay services. The authors who are affiliated with BG are employees of BCM and derive support through a professional services agreement with the BG. JRL has stock ownership in 23andMe, is a paid consultant for Regeneron Pharmaceuticals and Novartis, and is a co-inventor on multiple United States and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, and bacterial genomic fingerprinting.Funding StatementThis work was supported by the Baylor College of Medicine Precision Medicine Initiative Pilot Award to PL, National Human Genome Research Institute (NHGRI)/ National Heart Lung and Blood Institute (NHLBI) grant number UM1HG006542 to the Baylor Hopkins Center for Mendelian Genomics (BHCMG) to JRL, the National Institute of Neurological Disorders and Stroke (NINDS) R35NS105078 to JRL.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been performed in accordance with the research protocol approved by Institutional Review Boards at Baylor College of Medicine. A waiver of informed consent has been obtained (H-41191).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDetailed code for generation of the NAHR-deletion map, preparation of disease alleles, and calculation of disease burden is available at https://github.com/liu-lab/cnvNAHR/. https://github.com/liu-lab/cnvNAHR/ ER -